从TP53-突变性克隆性血液形成中与治疗相关的骨髓瘤的发病因子
Jonas Fullin1, Ebru Topçu1, Karolina A Zielińska1
1Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Leukemia
|December 17, 2025
概括
血液造血干细胞中的双基TP53突变导致基因组不稳定性和白血病转变,与单基突变不同. 非突变的p53无活化也促进了与治疗相关的AML/MDS.
科学领域:
- 血液学 血液学 血液学
- 癌症生物学 癌症生物学
- 遗传学 遗传学 是一个
背景情况:
- 与治疗相关的急性髓性白血病和骨髓质瘤 (t-AML/MDS) 是癌症治疗后的严重并发症.
- 具有TP53突变的克隆造血 (CH) 增加了t-AML/MDS的风险,但TP53等位状态的作用尚不清楚.
研究的目的:
- 调查血造干细胞和原生细胞 (HSPCs) 中的单基与双基TP53突变如何影响白血病的进展.
- 确定TP53等位体状态在t-AML/MDS发病过程中的预后影响.
主要方法:
- 开发了新的体外和体内小鼠模型来研究Trp53突变.
- 在治疗引起的压力下分析了克隆扩张和白血病转变.
主要成果:
- 单基因Trp53突变赋予了克隆适应性,但保持了基因组完整性.
- 双基Trp53突变导致基因组不稳定,对白血病转变至关重要.
- 过度表达MDM2模仿双基TP53突变效应,解释了一些TP53突变的AML/MDS病例.
结论:
- 阐明单基和双基TP53突变在t-AML/MDS发病过程中的不同作用.
- 支持将双基TP53突变AML/MDS分类为不同的临床实体.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Stem Cell Therapy for Tissue Regeneration
4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Lineage Commitment
4.0K
Commitment is the process whereby stem cells:
4.0K
Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K


